L. mono Differential Agar Base
L. mono Differential Agar Base has been recommended for the selective and differential isolation of Listeriamonocytogenes . Composition** Ingredients Gms / Litre
**Formula adjusted, standardized to suit performance parameters
Directions Suspend 36.02 grams in 460 ml distilled water. Heat to boiling to dissolve the medium completely. Sterilize by autoclaving
at15 lbs pressure (121°C) for 15 minutes. Cool to 45-50°C. Aseptically add sterile contents of 1 vial of L. mono Enrichment
Supplement I (FD214) and sterile rehydrated contents of L .mono Selective Supplement I (FD212), L .mono Selective
Supplement II (FD213). Mix well and pour into sterile Petri plates.
Warning : Lithium chloride is harmful. Avoid bodily contact and inhalation of vapours. On contact with skin wash with plenty
Principle And Interpretation Listeria monocytogenes is a gram-positive foodborne human pathogen responsible for serious infections in pregnant women
that may ultimately result in abortion, stillbirth, birth of a child with neonatal listeriosis and meningitis or primary bacteremia
in adults and juveniles. The pathogenicity of Listeria ivanovii for humans is uncertain. Since L. monocytogenes and L.innocua have similar biochemical properties, they cannot be differentiated on traditional media (PALCAM, Oxford). L. mono
Differential Agar Base is based on the formulation of Ottoviani and Agosti (1, 2) for the selective and differential isolation
of Listeria monocytogenes from food and animal feeds.
Meat peptone, casein enzymic hydrolysate, yeast extract and sodium pyruvate provide essential growth nutrients and
nitrogenous substances. Glucose is the fermentable carbohydrate. Sodium chloride maintains osmotic equilibrium. Phosphate
buffers the medium. Lithium chloride and added selective supplements (FD212 and FD213) inhibit accompanying microflora
and allow the growth of Listeria species. Listeria species hydrolyse the chromogenic substrate which produces green
coloured colonies. Differentiation of Listeria monocytogenes from other Listeria species is based on phosphatidylinositol-
specific phospholipase C (PIPLC) activity. Phospholipase C enzyme hydrolyses the purified substrate (FD214) added to the
medium resulting in an opaque halo around Listeria monocytogenes colonies. Quality Control Appearance Cream to yellow homogeneous free flowing powder Please refer disclaimer Overleaf. HiMedia Laboratories Technical Data Colour and Clarity of prepared medium Light amber coloured, opalescent gel forms in Petri plates Reaction Reaction of 7.2% w/v aqueous solution at 25°C. pH : 7.2±0.2 pH 7.00-7.40 Cultural Response Cultural characteristics observed with added sterile L. mono Selective supplement I (FD212), L. mono Selective Supplement II (FD213) and L.mono Enrichment supplement I (FD214) after an incubation at 35 - 37°C for 24 - 48 hours. Cultural Response Organism Inoculum Recovery Colour of PIPLC activity Cultural Response Candida albicans ATCC 10231Enterococcus faecalis ATCC >=10³
33090Listeria grayi ATCC 19120 50-100
opaquehalo aroundthe colonyexhibitingphophatidylinositolspecificphospholipaseacivity
opaquehalo aroundthe colonyexhibitingphosphatidylinositolspecificphospholipaseactivity
Storage and Shelf Life Store dehydrated powder and the prepared medium at 2-8º C in tightly closed container . Use before expiry date on the label. Reference 1. Ottaviani F., Ottaviani M., and Agosti M. (1997 a), Industrie Alimentari 36, 1-3. 2.Ottaviani F., Ottaviani M., and Agosti M. (1997 b), Quimper Froid Symposium Proceedings p. 6, A.D.R.I.A. Quimper, France, 16-18 June 1997. Please refer disclaimer Overleaf. HiMedia Laboratories Technical Data
User must ensure suitability of the product(s) in their application prior to use. Products conform solely to the information contained inthis and other related HiMedia™ publications. The information contained in this publication is based on our research and developmentwork and is to the best of our knowledge true and accurate. HiMedia™ Laboratories Pvt Ltd reserves the right to make changes tospecifications and information related to the products at any time. Products are not intended for human or animal or therapeutic use butfor laboratory,diagnostic, research or further manufacturing use only, unless otherwise specified. Statements contained herein should notbe considered as a warranty of any kind, expressed or implied, and no liability is accepted for infringement of any patents.
HiMedia Laboratories Pvt. Ltd. A-516,Swastik Disha Business Park,Via Vadhani Ind. Est., LBS Marg, Mumbai-400086, India. Customer care No.: 022-61471919 Email: [email protected]
GlaxoSmithKline Sector: Health care Recommendation: BUY Analyst: Casper Runge Albæk Tel. +45 89223700 E-mail: [email protected] GlaxoSmithKline takes an optimistic view of 2005 GlaxoSmithKline GlaxoSmithKline released its 2004 accounts – a year that was quite released reasonable demanding. We took special note of the following: accounts for 2004 �
Camouflage: Pay-for-Delay Jonathan Tickner annual savings to purchasers of drugs that would result fromeliminating reverse payment settlements could be in the region ofIn Gurney v Grimmer [see Endnote 1], Lawrence LJ said that whena matter has been compromised it “ assumes that a mutualconcession has been made by both parties and that each party hasgot something less than he claimed ”
L. mono Differential Agar Base
HiMedia Laboratories